Baseline clinical and imaging predictors of treatment response and overall survival of patients with metastatic melanoma undergoing immunotherapy

This publication has 13 references indexed in Scilit:

• Predicting Overall Survival in Patients With Metastatic Melanoma on Antiangiogenic Therapy and RECIST Stable Disease on Initial Posttherapy Images Using CT Texture Analysis
  American Journal of Roentgenology, 2015
• Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
  Journal of Clinical Oncology, 2015
• Prognostic role of lactate dehydrogenase in solid tumors: A systematic review and meta-analysis of 76 studies
  Acta Oncologica, 2015
• Metastatic Melanoma: Lactate Dehydrogenase Levels and CT Imaging Findings of Tumor Devascularization Allow Accurate Prediction of Survival in Patients Treated with Bevacizumab
  Radiology, 2014
• Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
  New England Journal of Medicine, 2010
• Prognostic Significance of Serum S100B Protein in High-Risk Surgically Resected Melanoma Patients Participating in Intergroup Trial ECOG 1694
  Journal of Clinical Oncology, 2009
• Melanoma epidemiology and trends
  Clinics in Dermatology, 2009
• New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
  European Journal of Cancer, 2009
• Long-Term Survival Analysis in Metastatic Melanoma: Serum S100B Is an Independent Prognostic Marker and Superior to LDH
  Onkologie, 2008
• Correlation of Computed Tomography and Positron Emission Tomography in Patients With Metastatic Gastrointestinal Stromal Tumor Treated at a Single Institution With Imatinib Mesylate: Proposal of New Computed Tomography Response Criteria
  Journal of Clinical Oncology, 2007